MA44874A - Thérapie génique pour traiter la mucopolysaccharidose de type ii - Google Patents

Thérapie génique pour traiter la mucopolysaccharidose de type ii

Info

Publication number
MA44874A
MA44874A MA044874A MA44874A MA44874A MA 44874 A MA44874 A MA 44874A MA 044874 A MA044874 A MA 044874A MA 44874 A MA44874 A MA 44874A MA 44874 A MA44874 A MA 44874A
Authority
MA
Morocco
Prior art keywords
gene therapy
mucopolysaccharidosis type
treat mucopolysaccharidosis
treat
type
Prior art date
Application number
MA044874A
Other languages
English (en)
Inventor
Christian Hinderer
James M Wilson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MA44874A publication Critical patent/MA44874A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA044874A 2016-04-15 2017-04-14 Thérapie génique pour traiter la mucopolysaccharidose de type ii MA44874A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323194P 2016-04-15 2016-04-15
US201662330938P 2016-05-03 2016-05-03
US201662337163P 2016-05-16 2016-05-16
US201662367780P 2016-07-28 2016-07-28
US201762452494P 2017-01-31 2017-01-31

Publications (1)

Publication Number Publication Date
MA44874A true MA44874A (fr) 2019-03-13

Family

ID=60042827

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044874A MA44874A (fr) 2016-04-15 2017-04-14 Thérapie génique pour traiter la mucopolysaccharidose de type ii

Country Status (11)

Country Link
US (2) US11253612B2 (fr)
EP (1) EP3452104A1 (fr)
JP (3) JP7171439B2 (fr)
KR (3) KR20230125339A (fr)
AU (2) AU2017250298B2 (fr)
BR (1) BR112018071156A2 (fr)
CA (1) CA3019427A1 (fr)
IL (2) IL262211B2 (fr)
MA (1) MA44874A (fr)
SG (2) SG11201808176TA (fr)
WO (1) WO2017181113A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191666A1 (fr) * 2017-04-14 2018-10-18 Regenxbio Inc. Traitement de la mucopolysaccharidose ii avec l'iduronate-2-sulfatase (ids) humaine recombinée produite par des cellules neurales ou gliales humaines
WO2019060662A1 (fr) * 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Thérapie génique pour le traitement de la mucopolysaccharidose de type ii
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
IL274430B2 (en) * 2017-11-08 2025-01-01 Novartis Gene Therapies Inc Means and method for preparing viral vectors and their uses
MX2020008932A (es) 2018-02-27 2020-10-01 Univ Pennsylvania Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
WO2019236949A1 (fr) 2018-06-08 2019-12-12 Avexis Inc. Dosage basé sur des cellules permettant de mesurer la puissance d'un produit médicamenteux
SG11202104295UA (en) * 2018-11-14 2021-06-29 Regenxbio Inc Gene therapy for neuronal ceroid lipofuscinoses
IL293684A (en) 2019-12-10 2022-08-01 Takeda Pharmaceuticals Co Adeno associated virus vectors for the treatment of hunter disease
EP4096631A1 (fr) * 2020-01-29 2022-12-07 RegenxBio Inc. Traitement de la mucopolysaccharidose ii avec de l'iduronate-2-sulfatase (ids) humaine recombinée produite par des cellules neurales ou gliales humaines
MX2022012407A (es) * 2020-04-06 2022-10-28 Homology Medicines Inc Composiciones de virus adenoasociados para la transferencia del gen ids y sus metodos de uso.
EP4162059A1 (fr) 2020-05-12 2023-04-12 The Trustees of The University of Pennsylvania Compositions pour la réduction spécifique à des drg d'expression transgénique
WO2022040530A2 (fr) * 2020-08-21 2022-02-24 Capsida, Inc. Compositions de virus pour traiter la mucopolysaccharidose ii
WO2022173605A2 (fr) * 2021-02-10 2022-08-18 Regenxbio Inc. Traitement de la mucopolysaccharidose ii avec de l'iduronate-2-sulfatase (ids) humaine recombinée
US20240366789A1 (en) * 2021-04-01 2024-11-07 The University Of North Carolina At Chapel Hill Aav-ids vectors for treatment of mucopolysaccharidosis ii
CN115820740A (zh) * 2021-09-16 2023-03-21 北京锦篮基因科技有限公司 用于治疗ⅱ型粘多糖贮积症的重组腺相关病毒载体及其应用
US20250295807A1 (en) 2021-11-15 2025-09-25 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
US20250115903A1 (en) * 2022-01-17 2025-04-10 Ryan T. Gill Compositions and methods for editing genomes
WO2025075963A1 (fr) * 2023-10-02 2025-04-10 Regenxbio Inc. Méthodes et formulations pour le traitement de la perte auditive associée à la mucopolysaccharidose de type ii avec de l'iduronate-2-sulfatase humaine recombinée

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE156704T1 (de) 1989-12-05 1997-08-15 Ramsey Foundation Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
FR2716893B1 (fr) * 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
US6190659B1 (en) 1996-09-17 2001-02-20 The Rockefeller University Bacterial plasmin binding protein and methods of use thereof
JP2001512142A (ja) 1997-07-31 2001-08-21 カイロン コーポレイション 宿主の免疫抑制を介するａａｖベクターの再投与を可能にする方法
PT1080202E (pt) 1998-05-27 2006-05-31 Avigen Inc Distribuicao de vectores aav codificando aadc intensificada por conveccao
WO2000033814A2 (fr) 1998-12-09 2000-06-15 Chiron Corporation Technique d'apport d'agents au systeme nerveux central
JP2002531489A (ja) 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系への神経栄養剤の投与
US7273618B2 (en) 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
ATE403715T1 (de) 1999-08-09 2008-08-15 Targeted Genetics Corp Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
US6569661B1 (en) 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en) 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6582692B1 (en) 1999-11-17 2003-06-24 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
ATE300952T1 (de) 1999-12-09 2005-08-15 Chiron Corp Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
CA2416492C (fr) 2000-07-18 2008-04-29 Duke University Traitement de la glycogenose de type ii
US20020014242A1 (en) 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
WO2002032449A2 (fr) 2000-10-13 2002-04-25 Chiron Corporation Procede de traitement d'accidents ischemiques affectant le systeme nerveux central
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
US20030165434A1 (en) 2001-04-20 2003-09-04 Chiron Corporation Delivery of polynucleotide agents to the central nervous system
CN103555677B (zh) 2001-11-13 2018-01-30 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2003052051A2 (fr) 2001-12-17 2003-06-26 The Trustees Of The University Of Pennsylvania Sequences du serotype 8 du virus associe a l'adenovirus (aav), vecteurs les contenant et utilisations correspondantes
US20070004743A1 (en) 2002-02-25 2007-01-04 Xiao Linda L Intranasal administration of mc4-r agonists
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
WO2004055157A2 (fr) 2002-08-13 2004-07-01 Whitley Chester B Procedes d'utilisation de vecteurs pour traiter des troubles metaboliques
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
DK3211085T3 (da) 2003-09-30 2021-06-21 Univ Pennsylvania Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7776312B2 (en) 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
AU2006217027A1 (en) 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
US8999678B2 (en) 2005-04-07 2015-04-07 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
US7456683B2 (en) 2005-06-09 2008-11-25 Panasonic Corporation Amplitude error compensating device and quadrature skew error compensating device
CA2620364A1 (fr) 2005-08-26 2007-03-01 David C. Yeomans Methodes de traitement des maux de tete par administration d'oxytocine
EP1986661B1 (fr) 2006-02-08 2018-08-29 Genzyme Corporation Therapie genique destinee a la maladie de niemann-pick de type a
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
EP1915986A1 (fr) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Fomulations lipidiques comprenant des facteurs de croissance
CA2680063A1 (fr) 2007-02-23 2008-08-28 University Of Florida Research Foundation, Inc. Compositions et procedes pour le traitement de maladies liees au stockage du glycogene
PT3252161T (pt) 2007-06-06 2022-02-01 Genzyme Corp Terapia genética para doenças do armazenamento lisossomal
EP2152240A4 (fr) 2007-06-08 2012-05-09 Healthpartners Res Foundation Compositions pharmaceutiques et procédés permettant d'amplifier le ciblage de composés thérapeutiques sur le système nerveux central
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP2058401A1 (fr) 2007-10-05 2009-05-13 Genethon Fourniture généralisée de gènes à des motoneurones utilisant l'injection périphérique de vecteurs AAV
WO2009075815A1 (fr) 2007-12-07 2009-06-18 Duke University Thérapie génique d'immunomodulation
US9265843B2 (en) 2008-03-27 2016-02-23 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
WO2010071832A1 (fr) 2008-12-19 2010-06-24 Nationwide Children's Hospital Administration de polynucléotides à travers la barrière hémato-encéphalique à l'aide de aav9 recombinant
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US7989502B2 (en) 2009-02-06 2011-08-02 Sri International Intranasal delivery of modafinil
EP2396343B1 (fr) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
US20110070241A1 (en) 2009-06-30 2011-03-24 Duke University Methods for modulating immune responses to aav gene therapy vectors
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
SG10201908848RA (en) 2010-03-29 2019-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
DK2826860T3 (en) 2010-04-23 2018-12-03 Univ Massachusetts CNS targeting AAV vectors and methods for their use
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2394667A1 (fr) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vecteurs et séquences pour le traitement de maladies
UA115648C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Доставка терапевтичних агентів до цнс
PL2593131T3 (pl) 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
RU2012154576A (ru) 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
CN104857504A (zh) 2010-06-25 2015-08-26 夏尔人类遗传性治疗公司 芳基硫酸酯酶a cns递送的方法和组合物
WO2012101671A1 (fr) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Procédé de production d'iduronate 2-sulfatase recombinante humaine
JP6042825B2 (ja) 2011-02-10 2016-12-14 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
ES2724800T3 (es) 2011-02-17 2019-09-16 Univ Pennsylvania Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9
CA2832151C (fr) 2011-03-31 2021-06-15 University Of Iowa Research Foundation Procedes et compositions pour traiter des maladies cerebrales
EP3495472B1 (fr) 2011-04-21 2023-11-15 Nationwide Children's Hospital, Inc. Produits de virus recombinant et procédés pour l'inhibition de l'expression de myotiline
US10196636B2 (en) 2011-04-21 2019-02-05 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
WO2012159052A2 (fr) 2011-05-18 2012-11-22 Children's Hospital Medical Center Administration ciblée de protéines à travers la barrière hémato-encéphalique
US20130039888A1 (en) 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
CA2842798C (fr) 2011-07-25 2021-02-23 Nationwide Children's Hospital, Inc. Produits viraux recombinants et procedes pour inhibition de l'expression de dux4
AU2012322811A1 (en) 2011-10-12 2014-05-01 Synageva Biopharma Corp. Recombinant human NaGlu protein and uses thereof
US9821149B2 (en) 2011-10-14 2017-11-21 Healthpartners Research & Education Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
EP4338797A3 (fr) 2011-12-02 2024-06-12 Armagen, Inc. Procédés et compositions pour augmenter l'activité d'arylsulfatase a dans le snc
MX367842B (es) 2012-02-07 2019-09-09 Global Bio Therapeutics Inc Método compartimentado de administración de ácidos nucleicos y composiciones y usos del mismo.
WO2013190059A1 (fr) 2012-06-21 2013-12-27 Association Institut De Myologie Délivrance généralisée dans un gène de vecteurs de traitement génique
EP2879719B1 (fr) 2012-08-01 2018-07-04 Nationwide Children's Hospital Administration intrathecale du virus associe de l'adeno type 9
US12024568B2 (en) 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
DK3115372T3 (da) 2012-11-27 2019-06-11 Biomarin Pharm Inc Målrettede terapeutiske lysosomale enzymfusionsproteiner og anvendelser deraf
WO2014125647A1 (fr) 2013-02-18 2014-08-21 富士通オプティカルコンポーネンツ株式会社 Dispositif photorécepteur
SG10201707319UA (en) 2013-03-15 2017-10-30 Univ Pennsylvania Compositions and methods for treating mpsi
EP2986632B1 (fr) 2013-04-20 2018-09-05 Research Institute at Nationwide Children's Hospital Administration de virus adéno-associé recombinant de constructions polynucléotidiques u7snarn ciblant l'exon 2
US10821154B2 (en) 2013-05-01 2020-11-03 Genzyme Corporation Compositions and methods for treating spinal muscular atrophy
CA2912678C (fr) 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Transfert genique au systeme nerveux central a mediation par un virus adeno-associe
BR112016001592A2 (pt) 2013-07-26 2017-11-28 Univ Iowa Res Found métodos e composições para o tratamento de doenças cerebrais
LT3702466T (lt) 2013-08-27 2023-02-27 Research Institute At Nationwide Children's Hospital Produktai ir būdai, skirti šoninės amiotrofinės sklerozės gydymui
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
CN105745326A (zh) 2013-10-24 2016-07-06 优尼科Ip有限公司 用于基因治疗神经疾病的aav-5假型载体
WO2015164723A1 (fr) * 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Procédés et compositions pour le traitement du cancer du sein métastatique et d'autres cancers dans le cerveau
EP3909602A1 (fr) 2014-04-25 2021-11-17 University of Florida Research Foundation, Inc. Méthodes permettant qu'un sujet reçoive des doses multiples de virus adéno-associé recombinant
KR20230067694A (ko) 2014-09-24 2023-05-16 시티 오브 호프 고효율 게놈 편집을 위한 아데노-관련 바이러스 벡터 변이체 및 이의 방법
CN107249646B (zh) 2014-12-16 2021-06-29 内布拉斯加大学董事会 用于青少年巴滕病的基因疗法
HRP20220050T1 (hr) 2015-05-15 2022-10-14 Regents Of The University Of Minnesota Adenoasocirani virus, namijenjen terapijskom unosu u središnji živčani sustav
EP3101125A1 (fr) 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Vecteurs viraux recombinés adéno-associés pour le traitement de la mucopolysaccharidose
LT3411484T (lt) 2016-02-05 2023-11-27 Emory University Viengrandžio arba sau pačiam komplementaraus adeno-asocijuoto viruso 9 injekcija į smegenų skystį
US10561894B2 (en) 2016-03-18 2020-02-18 Icon Health & Fitness, Inc. Treadmill with removable supports
BR112019009902A2 (pt) 2016-11-15 2019-08-13 Univ Minnesota método para prevenir ou inibir a deterioração neurocognitiva
WO2019060662A1 (fr) * 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Thérapie génique pour le traitement de la mucopolysaccharidose de type ii

Also Published As

Publication number Publication date
IL262211A (en) 2018-11-29
IL262211B2 (en) 2024-01-01
IL262211B1 (en) 2023-09-01
CA3019427A1 (fr) 2017-10-19
AU2017250298A1 (en) 2018-10-11
IL305449A (en) 2023-10-01
SG11201808176TA (en) 2018-10-30
SG10201912761UA (en) 2020-02-27
KR20230125339A (ko) 2023-08-29
JP7171439B2 (ja) 2022-11-15
JP2023011821A (ja) 2023-01-24
WO2017181113A1 (fr) 2017-10-19
IL305449B2 (en) 2026-01-01
EP3452104A1 (fr) 2019-03-13
KR20190008237A (ko) 2019-01-23
JP2019518002A (ja) 2019-06-27
BR112018071156A2 (pt) 2019-03-12
US11253612B2 (en) 2022-02-22
US20220125949A1 (en) 2022-04-28
IL305449B1 (en) 2025-09-01
JP2025170352A (ja) 2025-11-18
KR20250036262A (ko) 2025-03-13
AU2024287090A1 (en) 2025-03-13
US20190070311A1 (en) 2019-03-07
AU2017250298B2 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
MA43968A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type i
MA44874A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type ii
IL271085A (en) Bacteria for the treatment of disorders
MA50016A (fr) Thérapie génique médiée par aav9 pour traiter la mucopolysaccharidose de type i
IL257486A (en) Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
MA47847A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type i
EP3368656A4 (fr) Thérapie anticancéreuse ciblée
DK3262066T4 (da) Genterapi
HRP20190165T1 (hr) Genska terapija za fabryjevu bolest
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
PL3265053T3 (pl) Sposoby leczenia skóry
SMT202400506T1 (it) Terapia genica
MA47173A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type ii
EP3148536C0 (fr) Associations pharmaceutiques pour traiter le cancer
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale
IL259762B (en) Complement activity modulators
EP3717653A4 (fr) Thérapie génique pour la mucopolysaccharidose de type iiia
IL256206A (en) Mct4 inhibitors for treating disease
HUE056613T2 (hu) Komplementaktivitás modulátorai
PL3612237T3 (pl) Terapia genowa
IL269544A (en) Optimization of enzyme replacement therapy for treatment of homocystinuria
IL257764B (en) Methods for treatment of diseases
DK3302478T3 (da) Pac-1 kombinations behandling
ZA201706440B (en) Gene therapy to improve vision
HUE049392T2 (hu) Paroxizmális súlyos fájdalom kezelése